GO:0035456 response to interferon-beta: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035456 (response to interferon-beta) describes any cellular or organismal change triggered by interferon-beta, a type I interferon.
• Interferon-beta is a key cytokine in antiviral defense, immune regulation, and resolution of inflammation [1,8].
• The response involves JAK-STAT signaling, interferon-stimulated gene (ISG) induction, and modulation of lipid mediators.
• Dysregulated interferon-beta responses contribute to multiple sclerosis, lupus, and viral infections [3,6,8].
• Therapeutic interferon-beta is used in multiple sclerosis, but neutralizing antibodies and differential receptor expression can reduce efficacy [3,4].
• MicroRNAs and vitamin D status modulate interferon-beta responses, offering biomarkers and combination strategies [2,5].
Description
Interferon-beta (IFN-beta) is a type I interferon that plays a central role in antiviral immunity and immune modulation. The Gene Ontology term GO:0035456, response to interferon-beta, captures the diverse cellular and organismal changes that occur following IFN-beta stimulation, including alterations in gene expression, enzyme production, and secretion. This process is critical for host defense and is therapeutically exploited in diseases such as multiple sclerosis. Understanding the molecular players and regulatory mechanisms of response to interferon-beta is essential for developing biomarkers and optimizing interferon-based therapies [4,5]. This article integrates QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:0035456, covering its definition, core mechanisms, key genes, disease relevance, and experimental models.
response to interferon-beta At A Glance
| GO ID | GO:0035456 |
|---|---|
| GO term | response to interferon-beta |
| Ontology | biological_process |
| Synonym | response to beta-1 interferon; response to fiblaferon; response to fibroblast interferon; response to interferon beta |
| Major function | Mediates cellular changes upon IFN-beta stimulation, including antiviral defense, immune regulation, and resolution of inflammation |
| Cellular location | Extracellular space (IFN-beta), plasma membrane (receptor), cytoplasm and nucleus (signaling and transcription) |
| Key pathways | JAK-STAT signaling, interferon-stimulated gene (ISG) induction, lipid mediator regulation |
| Disease relevance | Multiple sclerosis, systemic lupus erythematosus, viral infections |
What Is GO:0035456?
According to the Gene Ontology, response to interferon-beta (GO:0035456) is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus. Interferon-beta is a type I interferon, and this term encompasses the immediate signaling events and downstream transcriptional and functional consequences of IFN-beta exposure.
Why Is response to interferon-beta Important in Cell Biology?
Response to interferon-beta is a fundamental biological process that bridges innate and adaptive immunity. It is the basis for interferon-beta therapy in multiple sclerosis and is implicated in autoimmune diseases such as lupus [3,6]. Moreover, viruses have evolved mechanisms to antagonize IFN-beta production, highlighting its importance in host-pathogen interactions. Studying GO:0035456 helps researchers identify therapeutic targets, biomarkers of treatment response, and strategies to modulate inflammation [1,2,5].
• Critical for antiviral defense by inducing interferon-stimulated genes that inhibit viral replication.
• Regulates resolution of acute airway inflammation through proresolving lipid mediators.
• Therapeutic target in multiple sclerosis, where IFN-beta reduces relapse rates.
• Neutralizing antibodies against IFN-beta can reduce treatment efficacy in multiple sclerosis.
• Differential expression of interferon receptor isoforms affects patient responses to IFN-beta therapy.
• MicroRNAs are emerging as regulators and biomarkers of IFN-beta response in multiple sclerosis.
• Myeloid-derived suppressor cell-derived IFN-beta exacerbates lupus by promoting T follicular helper cell responses.
• Vitamin D enhances responses to IFN-beta in multiple sclerosis, suggesting combination therapy.
• African American multiple sclerosis patients may have differential responses to IFN-beta-1a.
• Viral proteins such as varicellovirus bovinealpha 1 UL42 target IRF3 to inhibit IFN-beta production.
What Happens During response to interferon-beta?
IFN-beta Binding and Receptor Activation
In simple terms: Interferon-beta acts like a key that fits into a specific lock on the cell surface, starting a chain reaction inside the cell.
Interferon-beta binds to the type I interferon receptor (IFNAR), composed of IFNAR1 and IFNAR2 subunits. This binding activates receptor-associated JAK kinases, which phosphorylate STAT transcription factors. Differential expression of interferon receptor isoforms can influence the response to IFN-beta therapy in multiple sclerosis patients.
JAK-STAT Signaling and Gene Expression
In simple terms: The signal travels to the nucleus and turns on many antiviral and immune genes.
Phosphorylated STAT1 and STAT2 form a complex with IRF9, known as ISGF3, which translocates to the nucleus and binds to interferon-stimulated response elements (ISREs) in DNA. This induces hundreds of interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects.
Regulation of Proresolving Lipids
In simple terms: Interferon-beta helps the body produce molecules that calm inflammation.
Interferon-beta regulates the production of proresolving lipid mediators, such as resolvins and lipoxins, which promote the resolution of acute airway inflammation. This mechanism involves the modulation of enzymes like 12/15-lipoxygenase.
Modulation by MicroRNAs and Vitamin D
In simple terms: Other molecules can tweak how strongly the cell responds to interferon-beta.
MicroRNAs can regulate the expression of genes involved in the IFN-beta response, and specific miRNA signatures are associated with treatment response in multiple sclerosis. Vitamin D enhances IFN-beta responses, potentially through vitamin D receptor-mediated signaling, offering a strategy to improve therapy.
Viral Evasion and Antagonism
In simple terms: Some viruses fight back by blocking interferon-beta production.
Viruses have evolved proteins that inhibit IFN-beta production. For example, varicellovirus bovinealpha 1 UL42 targets host IRF3 to inhibit type I interferon beta production, thereby evading antiviral immunity.
Key Genes Involved in GO:0035456 response to interferon-beta
The following genes and proteins are central to the response to interferon-beta, based on verified literature and their roles in signaling, regulation, and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNB1 | Encodes interferon-beta cytokine | Central to antiviral and immunomodulatory responses; target for viral evasion |
| IFNAR1 | Type I interferon receptor subunit 1 | Mediates IFN-beta binding and signaling; receptor isoform expression affects therapy response |
| IFNAR2 | Type I interferon receptor subunit 2 | Mediates IFN-beta binding and signaling; differential expression impacts multiple sclerosis therapy |
| JAK1 | Janus kinase 1 | Phosphorylates STAT proteins downstream of IFNAR |
| TYK2 | Tyrosine kinase 2 | Phosphorylates STAT proteins downstream of IFNAR |
| STAT1 | Signal transducer and activator of transcription 1 | Forms ISGF3 complex to induce ISGs |
| STAT2 | Signal transducer and activator of transcription 2 | Forms ISGF3 complex to induce ISGs |
| IRF9 | Interferon regulatory factor 9 | Part of ISGF3 complex; binds ISREs |
| IRF3 | Interferon regulatory factor 3 | Key transcription factor for IFN-beta production; targeted by viral proteins |
| MX1 | Interferon-induced GTP-binding protein Mx1 | Antiviral effector ISG |
| OAS1 | 2'-5'-oligoadenylate synthetase 1 | Antiviral effector ISG |
| PKR | Protein kinase R | Antiviral effector ISG |
| ISG15 | Interferon-stimulated gene 15 | Ubiquitin-like modifier involved in antiviral defense |
| ADAR1 | Adenosine deaminase RNA specific | RNA editing enzyme induced by IFN-beta |
| 12/15-LOX | Arachidonate 12/15-lipoxygenase | Involved in proresolving lipid mediator synthesis regulated by IFN-beta |
| MDSC-derived IFN-beta | Interferon-beta produced by myeloid-derived suppressor cells | Promotes T follicular helper cell response and exacerbates lupus |
| miRNAs | MicroRNAs regulating IFN-beta response | Biomarkers and regulators in multiple sclerosis |
| Vitamin D receptor | Mediates vitamin D enhancement of IFN-beta responses | Potential combination therapy target in multiple sclerosis |
How Is response to interferon-beta Regulated?
The response to interferon-beta is tightly regulated at multiple levels. Receptor expression levels, particularly the ratio of IFNAR isoforms, can determine the strength and duration of signaling. Negative feedback mechanisms, including SOCS proteins and phosphatases, attenuate JAK-STAT signaling. MicroRNAs fine-tune the expression of IFN-beta pathway components, and their dysregulation is associated with altered treatment responses in multiple sclerosis. Additionally, vitamin D can enhance IFN-beta responses, suggesting nutritional and hormonal modulation. Viral proteins can directly inhibit IFN-beta production by targeting IRF3.
response to interferon-beta and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNB1 | Viral evasion, autoimmunity | Knockout mice, viral infection models |
| IFNAR1/2 | Multiple sclerosis therapy response | Patient-derived cells, receptor isoform knock-in |
| IRF3 | Viral antagonism of IFN-beta production | Knockout cells, viral infection |
| MDSC-derived IFN-beta | Systemic lupus erythematosus | Lupus-prone mice, MDSC co-culture |
| 12/15-LOX | Airway inflammation resolution | Knockout mice, airway inflammation models |
Multiple Sclerosis
Interferon-beta is a first-line therapy for relapsing-remitting multiple sclerosis, but a subset of patients develop neutralizing antibodies that reduce efficacy. Differential expression of interferon receptor isoforms and microRNA signatures can predict or influence treatment response [4,5]. Vitamin D status may also modulate responsiveness to IFN-beta. African American patients may exhibit differential responses to IFN-beta-1a.
Systemic Lupus Erythematosus
Myeloid-derived suppressor cells can produce interferon-beta, which promotes T follicular helper cell responses and exacerbates lupus development. This highlights the complex role of IFN-beta in autoimmunity, where it can be both protective and pathogenic depending on context.
Viral Infections
Interferon-beta is critical for antiviral defense, and viruses have evolved strategies to inhibit its production. For example, varicellovirus bovinealpha 1 UL42 targets IRF3 to block IFN-beta production, aiding viral evasion. Understanding these mechanisms can inform antiviral therapies.
Airway Inflammation
Interferon-beta regulates proresolving lipids to promote the resolution of acute airway inflammation, suggesting a role in inflammatory lung diseases.
From response to interferon-beta-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IFN-beta signaling? | Knockout cell line (e.g., CRISPR-Cas9) followed by IFN-beta stimulation and ISG reporter assay |
| Does a point mutation in IFNAR affect response? | Point-mutation knock-in cell line using CRISPR base editing or HDR |
| How does a tagged IFN-beta protein behave? | Knock-in of fluorescent or epitope tag at endogenous IFNB1 locus |
| Can overexpression of a miRNA modulate IFN-beta response? | Overexpression cell line with miRNA mimic or lentiviral vector |
| What is the transcriptomic response to IFN-beta? | RNA-seq of wild-type and knockout cells treated with IFN-beta |
| Does a viral protein inhibit IFN-beta production? | Overexpression of viral protein in cells followed by IFN-beta promoter reporter assay |
How to Study the response to interferon-beta Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs and pathways induced by IFN-beta |
| Proteomics | Protein abundance and modifications | Quantify JAK-STAT signaling components |
| ISRE-luciferase reporter | Transcriptional activity of ISGF3 | Screen for regulators of IFN-beta response |
| CRISPR knockout screen | Gene function in IFN-beta response | Identify novel antiviral or regulatory genes |
| Flow cytometry | Surface markers and cytokine production | Analyze immune cell responses to IFN-beta |
| ELISA | Cytokine levels (e.g., IFN-beta) | Measure IFN-beta production in cell supernatants |
| Western blot | Protein phosphorylation and expression | Validate STAT1 phosphorylation upon IFN-beta treatment |
| MicroRNA profiling | miRNA expression levels | Discover biomarkers of IFN-beta therapy response |
Transcriptomic Profiling (RNA-seq)
RNA sequencing measures global changes in gene expression upon IFN-beta stimulation, identifying interferon-stimulated genes and pathways. This method is widely used to study response to interferon-beta in multiple sclerosis patient samples and cell models.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics can quantify protein abundance and phosphorylation events in the JAK-STAT pathway after IFN-beta treatment, revealing dynamic signaling changes and potential biomarkers.
Reporter Assays and Imaging
Luciferase reporters driven by ISRE or IFN-beta promoters are used to measure pathway activation. Fluorescence microscopy can visualize STAT1 nuclear translocation or ISG protein localization in live cells.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate response to interferon-beta, such as those affecting ISG induction or viral resistance.
How CRISPR Can Be Used to Study GO:0035456 response to interferon-beta
Knockout
CRISPR-Cas9 knockout of genes such as IFNAR1, STAT1, or IRF3 can abolish or reduce response to interferon-beta, confirming their essential roles. Knockout cell lines are valuable for studying viral evasion mechanisms and identifying drug targets.
Point Mutation
Introducing specific point mutations (e.g., in IFNAR2 or STAT1) using CRISPR base editing or homology-directed repair can model patient-derived mutations that affect IFN-beta signaling and therapy response.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at the IFNB1 locus allows real-time tracking of IFN-beta expression and secretion. Similarly, tagging ISG proteins can reveal their localization dynamics upon stimulation.
Overexpression
Overexpression of microRNAs or viral proteins using CRISPR activation or lentiviral vectors can test their impact on IFN-beta production and signaling. For example, overexpressing viral UL42 inhibits IRF3-mediated IFN-beta production.
How EDITGENE Supports response to interferon-beta Research
Researchers studying response to interferon-beta-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with changes in expression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for response to interferon-beta research.
Frequently Asked Questions About response to interferon-beta
What is GO:0035456 response to interferon-beta?
GO:0035456 is a Gene Ontology biological process term that describes any change in a cell or organism resulting from an interferon-beta stimulus, including gene expression, secretion, and movement.
What genes are involved in response to interferon-beta?
Key genes include IFNB1, IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT2, IRF9, IRF3, and interferon-stimulated genes such as MX1, OAS1, and ISG15 [1,4,8].
How does interferon-beta signaling work?
Interferon-beta binds to the IFNAR receptor, activating JAK-STAT signaling, leading to ISGF3 formation and induction of interferon-stimulated genes.
What diseases are associated with interferon-beta response?
Multiple sclerosis, systemic lupus erythematosus, viral infections, and airway inflammation are linked to interferon-beta responses [1,3,6,8].
Why is interferon-beta used to treat multiple sclerosis?
Interferon-beta reduces relapse rates and modulates immune responses in multiple sclerosis, although neutralizing antibodies can reduce efficacy.
How do microRNAs affect interferon-beta response?
MicroRNAs can regulate the expression of interferon pathway components and are being studied as biomarkers of treatment response in multiple sclerosis.
Can vitamin D enhance interferon-beta therapy?
Yes, vitamin D has been shown to enhance responses to interferon-beta in multiple sclerosis, suggesting a potential combination strategy.
What role does IRF3 play in interferon-beta production?
IRF3 is a transcription factor essential for IFN-beta production; viral proteins such as varicellovirus bovinealpha 1 UL42 target IRF3 to inhibit IFN-beta.
How can CRISPR be used to study interferon-beta response?
CRISPR knockout, knock-in, and overexpression models allow functional validation of genes in the interferon-beta pathway, including receptor isoforms and signaling molecules [4,8].
What are the research methods to study response to interferon-beta?
Common methods include RNA-seq, proteomics, reporter assays, CRISPR screens, flow cytometry, and ELISA to measure gene expression, signaling, and cytokine production [1,5,8].
Conclusion
Response to interferon-beta (GO:0035456) is a vital biological process with broad implications for antiviral immunity, autoimmune diseases, and therapeutic interventions. Understanding its molecular mechanisms, key genes, and regulatory networks is essential for developing better diagnostics and treatments. CRISPR-based models and advanced omics technologies continue to unravel the complexities of this pathway, offering new opportunities for drug discovery and personalized medicine.
References
- 1. Sekheri M et al.. 2022. Interferon-β regulates proresolving lipids to promote the resolution of acute airway inflammation.. Proc Natl Acad Sci U S A 119(31):e2201146119 PMID: 35878041
- 2. Feng X et al.. 2019. Vitamin D enhances responses to interferon-β in MS.. Neurol Neuroimmunol Neuroinflamm 6(6):e622 PMID: 31582399
- 3. Hemmer B et al.. 2005. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.. Lancet Neurol 4(7):403-12 PMID: 15963443
- 4. Gilli F. 2010. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.. J Interferon Cytokine Res 30(10):733-41 PMID: 20874250
- 5. Pourseirafi M et al.. 2026. Uncovering the role of microRNAs in response to interferon-beta therapy among multiple sclerosis patients: A systematic review.. Mult Scler Relat Disord 111:107265 PMID: 42208462
- 6. Rui K et al.. 2026. Myeloid-Derived Suppressor Cell-Derived Interferon-β Promotes T Follicular Helper Cell Response and Exacerbates Lupus Development.. Arthritis Rheumatol 78(5):1088-1101 PMID: 41312596
- 7. Cree BA et al.. 2005. Response to interferon beta-1a treatment in African American multiple sclerosis patients.. Arch Neurol 62(11):1681-3 PMID: 16286540
- 8. Yin X et al.. 2025. Varicellovirus bovinealpha 1 UL42 targets host IRF3 to inhibit type I interferon β production.. Vet Microbiol 308:110654 PMID: 40749450
